

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

### STA atezolizumab for adjuvant treatment of resected non-small-cell lung cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Final appraisal determination

(when no ACD was issued)

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

One consultee stated that the NHS lung cancer screening pilot has not been rolled out nationally yet. They stated that this may affect how effectively early non-small cell lung cancer patients are diagnosed across the country and that this may lead to equality issues if adjuvant immunotherapy becomes available for patients. However, this is not considered to be an equalities issue by the committee as this would not affect people protected by equality legislation any differently than other groups included in the appraisal population.
--

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No
----

- |  |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Not applicable

**Approved by Associate Director (name):** Jasdeep Hayre

**Date:** 28 July 2022